{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T01:40:31Z","timestamp":1782351631000,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"PAICYT-UANL","award":["CS955-11"],"award-info":[{"award-number":["CS955-11"]}]},{"name":"PAICYT-UANL","award":["CN-420-10"],"award-info":[{"award-number":["CN-420-10"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.pbb.2020.172950","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T11:27:38Z","timestamp":1589282858000},"page":"172950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Arachidonyl-2\u2032-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB1R gene expression and reduces dyskinesias in a rat model of Parkinson's disease"],"prefix":"10.1016","volume":"194","author":[{"given":"Melissa","family":"Leija-Salazar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Berm\u00fadez de Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azucena","family":"Gonz\u00e1lez-Horta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Gonz\u00e1lez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2\u20133","key":"10.1016\/j.pbb.2020.172950_bb0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0014-2999(95)00661-3","article-title":"Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists","volume":"295","author":"Anderson","year":"1996","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.pbb.2020.172950_bb0010","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.tins.2013.06.003","article-title":"Advances in the pharmacological treatment of Parkinson\u2019s disease: targeting neurotransmitter systems","volume":"36","author":"Brichta","year":"2013","journal-title":"Trends Neurosci."},{"issue":"4","key":"10.1016\/j.pbb.2020.172950_bb0015","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.pbb.2011.06.012","article-title":"Progesterone prevents depression-like behavior in a model of Parkinson\u2019s disease induced by 6-hydroxydopamine in male rats","volume":"99","author":"Casas","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"8","key":"10.1016\/j.pbb.2020.172950_bb2015","first-page":"2694","article-title":"l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.pbb.2020.172950_bb0020","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nbd.2016.06.013","article-title":"Co-administration of cannabidiol and capsazepine reduces l-DOPA-induced dyskinesia in mice: possible mechanism of action","volume":"94","author":"Dos-Santos-Pereira","year":"2016","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.pbb.2020.172950_bb0025","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1111\/j.1755-5949.2010.00144.x","article-title":"Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders","volume":"16","author":"Fernandez-Ruiz","year":"2010","journal-title":"CNS Neurosci. Ther."},{"issue":"6","key":"10.1016\/j.pbb.2020.172950_bb0030","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1046\/j.1460-9568.2003.02896.x","article-title":"Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias","volume":"18","author":"Ferrer","year":"2003","journal-title":"Eur. J. Neurosci."},{"issue":"6","key":"10.1016\/j.pbb.2020.172950_bb0035","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/mds.10289","article-title":"Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson\u2019s disease","volume":"17","author":"Fox","year":"2002","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.pbb.2020.172950_bb0040","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/mds.1280","article-title":"Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia","volume":"17","author":"Fox","year":"2002","journal-title":"Mov. Disord."},{"issue":"Suppl(73)","key":"10.1016\/j.pbb.2020.172950_bb0045","first-page":"269","article-title":"Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes","author":"Garcia-Arencibia","year":"2009","journal-title":"J. Neural Transm."},{"issue":"2","key":"10.1016\/j.pbb.2020.172950_bb0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1034\/j.1600-0773.2003.930202.x","article-title":"The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats","volume":"93","author":"Gilgun-Sherki","year":"2003","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.pbb.2020.172950_bb0055","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pbb.2014.06.020","article-title":"Evaluation of the association between blood homocysteine concentration and the degree of behavioral symptoms in the 6-hydroxydopamine-induced Parkinsonism in rat","volume":"124","author":"Haghdoost-Yazdi","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"2","key":"10.1016\/j.pbb.2020.172950_bb0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0091-3057(80)90353-6","article-title":"Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA","volume":"12","author":"Hefti","year":"1980","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"11","key":"10.1016\/j.pbb.2020.172950_bb0065","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00702-003-0033-7","article-title":"Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain","volume":"110","author":"Hurley","year":"2003","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"1","key":"10.1016\/j.pbb.2020.172950_bb0070","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0306-4522(03)00070-8","article-title":"Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia","volume":"119","author":"Julian","year":"2003","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.pbb.2020.172950_bb0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12640-019-00109-8","article-title":"Cannabidiol and cannabinoid compounds as potential strategies for treating Parkinson\u2019s disease and l-DOPA-induced dyskinesia","volume":"37","author":"Junior","year":"2020","journal-title":"Neurotox. Res."},{"issue":"2","key":"10.1016\/j.pbb.2020.172950_bb0080","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.expneurol.2005.06.006","article-title":"Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson\u2019s disease?","volume":"197","author":"Lane","year":"2006","journal-title":"Exp. Neurol."},{"issue":"8","key":"10.1016\/j.pbb.2020.172950_bb0085","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/j.1476-5381.2012.02175.x","article-title":"The dynamic nature of type 1 cannabinoid receptor (CB(1)) gene transcription","volume":"167","author":"Laprairie","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.pbb.2020.172950_bb0090","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212delta delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"5","key":"10.1016\/j.pbb.2020.172950_bb0095","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/j.1471-4159.1993.tb09807.x","article-title":"Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study","volume":"61","author":"Mailleux","year":"1993","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.pbb.2020.172950_bb0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.expneurol.2005.11.002","article-title":"Motor complications in Parkinson\u2019s disease and the clinical significance of rotational behavior in the rat: have we wasted our time?","volume":"197","author":"Marin","year":"2006","journal-title":"Exp. Neurol."},{"issue":"3","key":"10.1016\/j.pbb.2020.172950_bb0105","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.neures.2011.12.006","article-title":"The cannabinoid agonist WIN55212-2 decreases l-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats","volume":"72","author":"Martinez","year":"2012","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.pbb.2020.172950_bb0110","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.nbd.2014.11.024","article-title":"Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats","volume":"74","author":"Martinez","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"4","key":"10.1016\/j.pbb.2020.172950_bb0115","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/cne.903270406","article-title":"Localization of cannabinoid receptor mRNA in rat brain","volume":"327","author":"Matsuda","year":"1993","journal-title":"J. Comp. Neurol."},{"issue":"3","key":"10.1016\/j.pbb.2020.172950_bb0120","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00002826-200405000-00003","article-title":"Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease","volume":"27","author":"Mesnage","year":"2004","journal-title":"Clin. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.pbb.2020.172950_bb0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.expneurol.2007.07.021","article-title":"Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson\u2019s disease: role of CB(1) and TRPV1 receptors","volume":"208","author":"Morgese","year":"2007","journal-title":"Exp. Neurol."},{"issue":"5","key":"10.1016\/j.pbb.2020.172950_bb0130","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0091-3057(81)90022-8","article-title":"Tetrahydrocannabinol potentiates reserpine-induced hypokinesia","volume":"15","author":"Moss","year":"1981","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"12","key":"10.1016\/j.pbb.2020.172950_bb0135","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/bph.13497","article-title":"An update on PPAR activation by cannabinoids","volume":"173","author":"O\u2019Sullivan","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2020.172950_bb0140","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2013"},{"issue":"1","key":"10.1016\/j.pbb.2020.172950_bb0145","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.expneurol.2003.09.001","article-title":"Ropinirole versus l-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson\u2019s disease: implications for dyskinesia","volume":"185","author":"Ravenscroft","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.pbb.2020.172950_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104646","article-title":"Targeting the cannabinoid receptor CB2 in a mouse model of l-DOPA induced dyskinesia","volume":"134","author":"Rentsch","year":"2020","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.pbb.2020.172950_bb0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0163-7258(02)00253-X","article-title":"The endogenous cannabinoid system and the basal ganglia. Biochemical, pharmacological, and therapeutic aspects","volume":"95","author":"Romero","year":"2002","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.pbb.2020.172950_bb0160","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/mds.10312","article-title":"Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson\u2019s disease","volume":"18","author":"Segovia","year":"2003","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.pbb.2020.172950_bb0165","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","article-title":"Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study","volume":"57","author":"Sieradzan","year":"2001","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.pbb.2020.172950_bb0170","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1006\/exnr.2001.7649","article-title":"Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson\u2019s disease","volume":"169","author":"Silverdale","year":"2001","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.pbb.2020.172950_bb0175","first-page":"2173","article-title":"The CB1 cannabinoid receptor agonist reduces l-DOPA-induced motor fluctuation and ERK1\/2 phosphorylation in 6-OHDA-lesioned rats","volume":"8","author":"Song","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"issue":"1","key":"10.1016\/j.pbb.2020.172950_bb0180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/can.2017.0002","article-title":"Cannabinoids in Parkinson\u2019s disease","volume":"2","author":"Stampanoni Bassi","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"issue":"9","key":"10.1016\/j.pbb.2020.172950_bb0185","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1096\/fj.04-3010fje","article-title":"A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson\u2019s disease","volume":"19","author":"van der Stelt","year":"2005","journal-title":"FASEB J."},{"issue":"Pt 4","key":"10.1016\/j.pbb.2020.172950_bb0190","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/brain\/awu409","article-title":"Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson\u2019s disease: a dose-finding study","volume":"138","author":"Svenningsson","year":"2015","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.pbb.2020.172950_bb0195","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"124","author":"Tysnes","year":"2017","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"6220","key":"10.1016\/j.pbb.2020.172950_bb0200","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.pbb.2020.172950_bb0205","doi-asserted-by":"crossref","first-page":"e621","DOI":"10.1016\/j.neurobiolaging.2011.02.009","article-title":"Regional changes in type 1 cannabinoid receptor availability in Parkinson\u2019s disease in vivo","volume":"33","author":"Van Laere","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.pbb.2020.172950_bb0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fphar.2012.00021","article-title":"CB1 cannabinoid receptor expression in the striatum: association with corticostriatal circuits and developmental regulation","volume":"3","author":"Van Waes","year":"2012","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pbb.2020.172950_bb0215","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.brainres.2010.09.086","article-title":"The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats","volume":"1363","author":"Walsh","year":"2010","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.pbb.2020.172950_bb0220","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3940(99)00762-4","article-title":"Chronic l-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats","volume":"276","author":"Zeng","year":"1999","journal-title":"Neurosci. Lett."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305720300265?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305720300265?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:38:51Z","timestamp":1758775131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305720300265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":45,"alternative-id":["S0091305720300265"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2020.172950","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arachidonyl-2\u2032-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB1R gene expression and reduces dyskinesias in a rat model of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2020.172950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"172950"}}